<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34279169</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>1-2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Italian adaptation of the Beaumont Behavioral Inventory (BBI): psychometric properties and clinical usability.</ArticleTitle><Pagination><StartPage>81</StartPage><EndPage>86</EndPage><MedlinePgn>81-86</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.1946085</ELocationID><Abstract><AbstractText><b>Objective.</b> Up to 50% of patients affected by amyotrophic lateral sclerosis (ALS) show behavioral changes within the <i>spectrum</i> of frontotemporal degeneration (FTD). Behavioral dysfunctions in ALS patients negatively impact on management, prognosis and survival. It is, thus, crucial to develop ALS-specific psychometric tools for early detecting alterations in behavior. This study aimed at investigating psychometric properties and feasibility of the Beaumont Behavioral Impairment (BBI), a proxy-report questionnaire designed to screen for FTD-like behavioral symptoms in ALS patients.<b>Methods.</b> Ninety ALS patients were compared to 100 healthy participants (HPs) on the BBI. ALS patients underwent clinical, cognitive, mood/anxiety and further behavioral (Frontal System Behavior Scale, FrSBe; Frontal Behavioral Inventory, FBI) evaluation. Validity, reliability, sensitivity and specificity of the BBI were assessed.<b>Results.</b> The BBI was significantly related to FrSBe and FBI scores, whereas not to other measures. A Principal Component Analysis yielded a mono-component structure; Cronbach's &#x3b1; was .93. The BBI proved to be sensitive to changes in behavior as well as to discriminate between different degrees of dysfunction. By addressing the FrSBe as the gold standard, the BBI reached optimal sensitivity (85.7%) and specificity (79.7%) at a cutoff of 10.5. Moreover, the BBI proved to be more accurate than the FrSBe and the FBI in clinical classifications.<b>Conclusion.</b> The BBI showed high internal consistency, as well as good construct, convergent and divergent validity. Its clinical usability is encouraged in ALS patients as being able to sensitively and specifically detect FTD-like behavioral changes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iazzolino</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, University of Turin, ALS Centre, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pain</LastName><ForeName>Debora</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Istituti Clinici Scientifici Maugeri, IRCCS Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laura</LastName><ForeName>Peotta</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, University of Turin, ALS Centre, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aiello</LastName><ForeName>Edoardo N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, University of Milano-Bicocca, Monza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallucci</LastName><ForeName>Marcello</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Milan Center for Neuroscience, University of Milano-Bicocca, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radici</LastName><ForeName>Alice</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Istituti Clinici Scientifici Maugeri, IRCCS Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palumbo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, University of Turin, ALS Centre, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, University of Turin, ALS Centre, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, University of Turin, ALS Centre, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, University of Turin, ALS Centre, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Istituti Clinici Scientifici Maugeri, IRCCS Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>"Rita Levi Montalcini" Department of Neuroscience, University of Turin, ALS Centre, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SC Neurologia 1U, Azienda Ospedaliero-Universitaria Citt&#xe0; della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTD</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">behavioral impairment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>19</Day><Hour>12</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34279169</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.1946085</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>